56724 Federal Register / Vol. 70, No. 187 / Wednesday, September 28, 2005 / Notices 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

into the building by non-government 

employees. Persons without a government 

I.D. will need to show a photo I.D. and signin at the security desk upon entering the 

building. 

Information is also available on the 

Institute’s/Center’s home page: 

www.copr.nih.gov, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: September 21, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–19386 Filed 9–27–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Meeting: Secretary’s 

Advisory Committee on Genetics, 

Health, and Society 

Pursuant to Public Law 92–463, 

notice is hereby given of the eighth 

meeting of the Secretary’s Advisory 

Committee on Genetics, Health, and 

Society (SACGHS), U.S. Public Health 

Service. The meeting will be held from 

8:30 a.m. to 6 p.m. on October 19, 2005 

and 8:30 a.m. to 5 p.m. on October 20, 

2005 at the Bethesda North Marriott 

Hotel, 5701 Marinelli Road, North 

Bethesda, Maryland. The meeting will 

be open to the public with attendance 

limited to space available. The meeting 

will be webcast. 

The first half of the meeting will be 

devoted to the issue of large population 

studies of genetic variation, the 

environment and common disease. The 

Committee is working to identify salient 

scientific, ethical, and policy issues and 

questions associated with such studies 

and processes that could be employed to 

address them. On October 19, the 

Committee will gather input from 

several leaders in science and bioethics 

about the policy issues and how to 

address them, including mechanisms for 

engaging the general public. October 

20th will be devoted to the further 

exploration of current issues in 

pharmacogenomics. The Committee is 

developing a report to the Secretary on 

this topic, and at this meeting they will 

explore the financial and economic 

considerations involved in integrating 

pharmacogenomics into clinical practice 

as well as delve more deeply into 

certain ethical, legal and social issues 

raised by pharmacogenomics. Time will 

be provided each day for public 

comments, and the public is encouraged 

to provide its perspectives to the 

committee on these topics or any others 

related to the development and use of 

genetic technologies. 

Under authority of 42 U.S.C. 217a, 

Section 222 of the Public Health Service 

Act, as amended, the Department of 

Health and Human Services established 

SACGHS to serve as a public forum for 

deliberations on the broad range of 

human health and societal issues raised 

by the development and use of genetic 

technologies and, as warranted, to 

provide advice on these issues. The 

draft meeting agenda and other 

information about SACGHS, including 

information about access to the webcast, 

will be available at the following Web 

site: http://www4.od.nih.gov/oba/ 

sacghs.htm. 

The Committee would welcome 

hearing from anyone wishing to provide 

public comment on any issue related to 

genetics, health and society. Individuals 

who would like to provide public 

comment or who plan to attend the 

meeting and need special assistance, 

such as sign language interpretation or 

other reasonable accommodations, 

should notify the SACGHS Executive 

Secretary, Ms. Sarah Carr, by telephone 

at (301) 496–9838 or e-mail at 

sc112c@nih.gov. The SACGHS office is 

located at 6705 Rockledge Drive, Suite 

750, Bethesda, MD 20892. 

Dated: September 21, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–19387 Filed 9–27–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Meeting; Interagency Autism 

Coordinating Committee 

The National Institutes of Health 

(NIH) hereby announces a meeting of 

the Interagency Autism Coordinating 

Committee to be held on November 18, 

2005, on the NIH campus in Bethesda, 

Maryland. 

The Children’s Health Act of 2000 

(Pub. L. 106–310), Title I, Section 104, 

mandated the establishment of an 

Interagency Autism Coordinating 

Committee (IACC) to coordinate autism 

research and other efforts within the 

Department of Health and Human 

Services (HHS). In April 2001, the HHS 

Secretary delegated the authority to 

establish the IACC to the NIH. The 

National Institute of Mental Health 

(NIMH) at the NIH has been designated 

the lead for this activity. 

The IACC meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the contact person listed below in 

advance of the meeting. 

Name of Committee: Interagency Autism 

Coordinating Committee. 

Date: November 18, 2005. 

Time: 9 a.m.–4:30 p.m. 

Agenda: Discussion of autism activities 

across Federal agencies. 

Place: National Institutes of Health, 31 

Center Drive, Building 31, Conference Room 

10 (6th floor), Bethesda, Maryland 20892. 

Contact Person: Ann Wagner, Ph.D., 

Division of Services and Intervention 

Research, National Institute of Mental Health, 

NIH, 6001 Executive Boulevard, Room 6184, 

MSC 9617, Bethesda, Maryland 20892, Email: awagner@mail.nih.gov, Phone: (301) 

443–5944. 

Any member of the public interested in 

presenting oral comments to the Committee 

may notify the contact person listed on this 

notice at least 5 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. 

Presentations may be limited to 5 minutes; 

both printed and electronic copies are 

requested for the record. In addition, any 

interested person may file written comments 

Federal Register / Vol. 70, No. 187 / Wednesday, September 28, 2005 / Notices 56725 

with the Committee by forwarding his/her 

statement to the contact person listed on this 

notice. The statement should include the 

name, address, telephone number, and, when 

applicable, the business or professional 

affiliation of the interested person. 

Information about the meeting and online 

registration forms are also available online on 

the NIMH homepage at http:// 

www.nimh.nih.gov/autismiacc/index.cfm. 

Dated: September 21, 2005. 

Raynard S. Kington, 

Deputy Director, National Institutes of Health. 

[FR Doc. 05–19377 Filed 9–27–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (U.S.C. Appendix 2), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, SBIR 

Topics 200 (Phase II) and 201 (Phase II), 

Date: October 19, 2005. 

Time: 12 p.m. to 2 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6130 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Joyce C. Pegues, PhD, 

Scientific Review Administrator, Special 

Review and Logistics Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., 7149, 

Bethesda, MD 20892, 301/594–1286, 

peguesj@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 21, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–19382 Filed 9–27–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(C)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Nursing Research Initial Review Group. 

Date: October 20–21, 2005. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Jeffrey M. Chernak, PhD., 

Scientific Review Administrator, Office of 

Review, National Institute of Nursing 

Research, 6701 Democracy Plaza, Suite 712, 

MSC 4870, Bethesda, MD 20817; (301) 402–

6959, chernak@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.361, Nursing Research, 

National Institutes of Health, HHS) 

Dated: September 21, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–19380 Filed 9–27–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, 

Medication Development Research 

Subcommittee. 

Date: October 5, 2005. 

Time: 8:30 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Paul A. Coulis, PhD, 

Health Scientist Administrator, Office of 

Extramural Affairs, National Institute on 

Drug Abuse, National Institutes of Health, 

DHHS, 6101 Executive Boulevard, Suite 220, 

Bethesda, MD 20892–8401, 301–443–2105. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, Health 

Services Research Subcommittee. 

Date: October 6–7, 2005. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Gerald L. McLaughlin, 

PhD, Scientific Review Administrator, Office 

of Extramural Affairs, National Institute on 

Drug Abuse, NIH, DHHS Room 220, MSC 

8401, 6101 Executive Blvd., Bethesda, MD 

20892–8401, 301–402–6626, gm145@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute on 

Drug Abuse Initial Review Group, Treatment 

Research Subcommittee. 

Date: October 6–7, 2005. 

Time: 9 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Kesinee Nimit, MD, Health 

Scientist Administrator, Office of Extramural 

Affairs, National Institute on Drug Abuse, 

NIH, DHHS Room 220, MSC 8401, 6101 

Executive Boulevard, Bethesda, MD 20892–

8401, 301–435–1432. 

This notice is being published less than 15 

days prior to the meeting due to the timing